^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Squamous Cell Skin Cancer |
| Drug: | Unloxcyt (cosibelimab-ipdl) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma
Published date:
12/13/2024
Excerpt:
On December 13, 2024, the Food and Drug Administration approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.), a programmed death ligand-1 (PD-L1) blocking antibody, for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.
Trial ID: